LEGEND BIOTECH ($LEGN) posted quarterly earnings results on Monday, August 11th. The company reported earnings of -$0.34 per share, missing estimates of -$0.15 by $0.19. The company also reported revenue of $255,060,000, beating estimates of $233,573,002 by $21,486,998.
You can see Quiver Quantitative's $LEGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LEGEND BIOTECH Hedge Fund Activity
We have seen 99 institutional investors add shares of LEGEND BIOTECH stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 7,506,934 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $254,710,270
- CITADEL ADVISORS LLC removed 2,749,683 shares (-94.7%) from their portfolio in Q1 2025, for an estimated $93,296,744
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,824,735 shares (-80.4%) from their portfolio in Q2 2025, for an estimated $64,759,845
- GOLDMAN SACHS GROUP INC removed 1,469,440 shares (-59.0%) from their portfolio in Q1 2025, for an estimated $49,858,099
- WESTFIELD CAPITAL MANAGEMENT CO LP added 1,203,871 shares (+21.1%) to their portfolio in Q1 2025, for an estimated $40,847,343
- MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. removed 989,397 shares (-98.5%) from their portfolio in Q2 2025, for an estimated $35,113,699
- BALYASNY ASSET MANAGEMENT L.P. removed 898,534 shares (-81.7%) from their portfolio in Q1 2025, for an estimated $30,487,258
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LEGEND BIOTECH Analyst Ratings
Wall Street analysts have issued reports on $LEGN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/17/2025
- UBS issued a "Buy" rating on 07/02/2025
- Truist Securities issued a "Buy" rating on 05/14/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/14/2025
- RBC Capital issued a "Outperform" rating on 04/22/2025
- Morgan Stanley issued a "Overweight" rating on 03/17/2025
To track analyst ratings and price targets for LEGEND BIOTECH, check out Quiver Quantitative's $LEGN forecast page.
LEGEND BIOTECH Price Targets
Multiple analysts have issued price targets for $LEGN recently. We have seen 6 analysts offer price targets for $LEGN in the last 6 months, with a median target of $73.0.
Here are some recent targets:
- Mitchell Kapoor from HC Wainwright & Co. set a target price of $75.0 on 07/17/2025
- Matthew Harrison from Morgan Stanley set a target price of $81.0 on 07/10/2025
- Ashwani Verma from UBS set a target price of $54.0 on 07/02/2025
- Asthika Goonewardene from Truist Securities set a target price of $71.0 on 05/14/2025
- Rick Bienkowski from Cantor Fitzgerald set a target price of $55.0 on 05/14/2025
- Brian Abrahams from RBC Capital set a target price of $84.0 on 04/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
